A fraction of patients with a common form of the bleeding disorder hemophilia develop anallergic reaction to the blood-clotting treatment they need to keep them alive. But using gene therapy, University of Florida researchers were able to reverse this reaction and provide long-lasting treatment for the disease in an animal model, according to findings published today in the journal EMBO Molecular Medicine.
If successful in humans, gene therapy could not only provide much-needed therapy for patients with hemophilia B, but also spare them from costly and difficult treatment regimens, said Roland Herzog, Ph.D., a professor of pediatrics in the UF College of Medicine and a senior author on the paper.
Read the full, original story here: Gene therapy study produces promising results for hemophilia B patients
